Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Total Non-Current Liabilities data on file, last reported at $119.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 18.37% year-over-year to $119.1 million; the trailing twelve-month figure through Mar 2026 stood at $119.1 million (up 18.37% YoY), and the FY2025 full-year result was $117.5 million, up 15.87% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $119.1 million, up from $117.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $119.1 million in Q1 2026 and bottomed at $77.3 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $99.2 million (2023), against an average of $99.4 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 73.86%; it then slipped 6.1% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $92.3 million in 2022, then rose by 7.17% to $99.0 million in 2023, then advanced by 2.46% to $101.4 million in 2024, then increased by 15.87% to $117.5 million in 2025, then grew by 1.34% to $119.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $119.1 million (Q1 2026), $117.5 million (Q4 2025), and $113.8 million (Q3 2025), per Business Quant data.

Peer Comparison